While the primary endpoints of the two pivotal studies conducted were not met, a secondary analysis of the data demonstrated that a molecule acting specifically on amyloid-beta can slow cognitive decline in patients with mild AD.

FORBES: Solving The Fatal Puzzle Of Alzheimer's Disease